- Home
- POM vs BOLT Comparison
POM vs BOLT Comparison
Compare POM & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | POM | BOLT |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | China | United States |
| Employees | 165 | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3M | 10.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | POM | BOLT |
|---|---|---|
| Price | $1.53 | $3.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $34.00 |
| AVG Volume (30 Days) | ★ 358.1K | 30.5K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,695,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $133.33 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.07 |
| 52 Week Low | $0.06 | $3.75 |
| 52 Week High | $6.43 | $7.20 |
Technical Indicators
Market Signals| Indicator | POM | BOLT |
|---|---|---|
| Relative Strength Index (RSI) | 72.06 | 36.20 |
| Support Level | $0.17 | N/A |
| Resistance Level | $5.00 | $5.05 |
| Average True Range (ATR) | 0.20 | 0.28 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 72.92 | 6.06 |
Price Performance
Historical ComparisonAbout POM POMDOCTOR LIMITED American Depositary Shares
Pomdoctor Ltd is an online medical services platform for chronic diseases in China. With a focus on chronic disease management and pharmaceutical services, its business model forms a one-stop platform for medical services, which organically connects patients to doctors and pharmaceutical products. Its experience in tackling chronic diseases can be traced back to the launch of its platform on mobile devices. The company operates in two segments: Internet hospital, and Pharmaceutical supply chain. The majority of its revenue is derived from the Pharmaceutical supply chain segment.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.